EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech

2022.10.13

Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022”

2022.08.15

EssexBio awarded “2021 China Pharmaceutical Industry Top 100 Series List” and “2022 China Pharmaceutical Brands List”

2022.07.15

Date

Title

2022-04-08

First Patient Dosed in a Global Multi-Centre Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for treatment of Ophthalmic Diseases in the EU

2022-03-22

Essex Bio-Technology Announces 2021 Financial Results Achieves an increase of 58% in Profit-After-Tax to HK$346.0 million and Turnover Growth of 67.4% to HK$1,637.7 million

2021-12-20

Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value

2021-11-10

First Patient First Visit Completed in the PRC in a Phase 3 Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)

2021-10-27

Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)

2021-08-12

Essex Bio-Technology Reports First Half 2021 Financial Results

2021-07-25

Essex Bio-Technology Listed on Two Authoritative Lists

2021-07-19

First Patient First Visit Completed in the PRC in Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT